TY - JOUR
T1 - Nociceptive, neuropathic, or nociplastic low back pain?
T2 - The low back pain phenotyping (BACPAP) consortium's international and multidisciplinary consensus recommendations
AU - Nijs, Jo
AU - Kosek, Eva
AU - Chiarotto, Alessandro
AU - Cook, Chad
AU - Danneels, Lieven A
AU - Fernández-de-Las-Peñas, César
AU - Hodges, Paul W
AU - Koes, Bart
AU - Louw, Adriaan
AU - Ostelo, Raymond
AU - Scholten-Peeters, Gwendolyne G M
AU - Sterling, Michele
AU - Alkassabi, Othman
AU - Alsobayel, Hana
AU - Beales, Darren
AU - Bilika, Paraskevi
AU - Clark, Jacqui R
AU - De Baets, Liesbet
AU - Demoulin, Christophe
AU - de Zoete, Rutger M J
AU - Elma, Ömer
AU - Gutke, Annelie
AU - Hanafi, Rikard
AU - Hotz Boendermaker, Sabina
AU - Huysmans, Eva
AU - Kapreli, Eleni
AU - Lundberg, Mari
AU - Malfliet, Anneleen
AU - Meziat Filho, Ney
AU - Reis, Felipe J J
AU - Voogt, Lennard
AU - Zimney, Kory
AU - Smeets, Rob
AU - Morlion, Bart
AU - de Vlam, Kurt
AU - George, Steven Z
N1 - Copyright © 2024 Elsevier Ltd. All rights reserved.
PY - 2024/3
Y1 - 2024/3
N2 - The potential to classify low back pain as being characterised by dominant nociceptive, neuropathic, or nociplastic mechanisms is a clinically relevant issue. Preliminary evidence suggests that these low back pain phenotypes might respond differently to treatments; however, more research must be done before making specific recommendations. Accordingly, the low back pain phenotyping (BACPAP) consortium was established as a group of 36 clinicians and researchers from 13 countries (five continents) and 29 institutions, to apply a modified Nominal Group Technique methodology to develop international and multidisciplinary consensus recommendations to provide guidance for identifying the dominant pain phenotype in patients with low back pain, and potentially adapt pain management strategies. The BACPAP consortium's recommendations are also intended to provide direction for future clinical research by building on the established clinical criteria for neuropathic and nociplastic pain. The BACPAP consortium's consensus recommendations are a necessary early step in the process to determine if personalised pain medicine based on pain phenotypes is feasible for low back pain management. Therefore, these recommendations are not ready to be implemented in clinical practice until additional evidence is generated that is specific to these low back pain phenotypes.
AB - The potential to classify low back pain as being characterised by dominant nociceptive, neuropathic, or nociplastic mechanisms is a clinically relevant issue. Preliminary evidence suggests that these low back pain phenotypes might respond differently to treatments; however, more research must be done before making specific recommendations. Accordingly, the low back pain phenotyping (BACPAP) consortium was established as a group of 36 clinicians and researchers from 13 countries (five continents) and 29 institutions, to apply a modified Nominal Group Technique methodology to develop international and multidisciplinary consensus recommendations to provide guidance for identifying the dominant pain phenotype in patients with low back pain, and potentially adapt pain management strategies. The BACPAP consortium's recommendations are also intended to provide direction for future clinical research by building on the established clinical criteria for neuropathic and nociplastic pain. The BACPAP consortium's consensus recommendations are a necessary early step in the process to determine if personalised pain medicine based on pain phenotypes is feasible for low back pain management. Therefore, these recommendations are not ready to be implemented in clinical practice until additional evidence is generated that is specific to these low back pain phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=85184048058&partnerID=8YFLogxK
U2 - 10.1016/S2665-9913(23)00324-7
DO - 10.1016/S2665-9913(23)00324-7
M3 - Article
C2 - 38310923
VL - 6
SP - 178
EP - 188
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
SN - 2665-9913
IS - 3
ER -